DEVELOPMENTAL FUNDS ? ABSTRACT Developmental Funds at KCI provide an important and essential source of funds in support of the Cancer Center?s investment in strategic initiatives. These initiatives are formalized through extensive planning and evaluation processes. During the past funding period, CCSG Developmental Funds were used in two key areas; 1) the recruitment of a key investigator in a Program leadership role, and 2) support of strategic pilot projects. CCSG funds were significantly augmented by institutional support to further recruitment efforts and provide funds for pilot projects aligned with KCI?s strategic priorities. Specifically, during the current grant cycle (12/1/2015 to 11/30/2019), $214,813 of CCSG Developmental Funds was augmented by an additional $14.8 million of institutional support to provide valuable support for 51 pilot projects consistent with the strategic vision of KCI and the recruitment of 36 new faculty, including 11 early stage investigators. The completed pilot projects have resulted in a five-fold return on investment measured by success in obtaining peer reviewed extramural funding. Additionally, new faculty level scientists have published 226 peer reviewed articles, secured 59 grant awards, and activated 129 clinical trials since their arrival. CCSG Developmental Funds in the amount of $55,550 are requested to fund pilot projects in the five areas of the Cancer Center?s focused future development. CCSG Developmental Funds, invested in pilot projects and augmented with institutional funding, have successfully driven innovative research and have led to extramurally funded projects over the course of the current grant cycle. This trend is expected to continue into the years to come, as KCI pursues the goals established in the strategic plan and engages with community partners to develop innovative projects that address the specific needs of the catchment area.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA022453-39
Application #
10088981
Study Section
Special Emphasis Panel (ZCA1)
Project Start
1997-08-08
Project End
2025-11-30
Budget Start
2020-12-15
Budget End
2021-11-30
Support Year
39
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Wayne State University
Department
Type
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
Kraniak, Janice M; Chalasani, Anita; Wallace, Margaret R et al. (2018) Development of 3D culture models of plexiform neurofibroma and initial application for phenotypic characterization and drug screening. Exp Neurol 299:289-298
An, Myunggi; Yu, Chunsong; Xi, Jingchao et al. (2018) Induction of necrotic cell death and activation of STING in the tumor microenvironment via cationic silica nanoparticles leading to enhanced antitumor immunity. Nanoscale 10:9311-9319
Neslund-Dudas, Christine M; McBride, Russell B; Kandegedara, Ashoka et al. (2018) Association between cadmium and androgen receptor protein expression differs in prostate tumors of African American and European American men. J Trace Elem Med Biol 48:233-238
Wu, Jheng-Yu; Xiang, Shengyan; Zhang, Mu et al. (2018) Histone deacetylase 6 (HDAC6) deacetylates extracellular signal-regulated kinase 1 (ERK1) and thereby stimulates ERK1 activity. J Biol Chem 293:1976-1993
Negmeldin, Ahmed T; Knoff, Joseph R; Pflum, Mary Kay H (2018) The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity. Eur J Med Chem 143:1790-1806
Tamura, Koji; Yu, Jun; Hata, Tatsuo et al. (2018) Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer. Proc Natl Acad Sci U S A 115:4767-4772
Matherly, Larry H; Hou, Zhanjun; Gangjee, Aleem (2018) The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer. Cancer Chemother Pharmacol 81:1-15
Pollack, Murray M; Holubkov, Richard; Reeder, Ron et al. (2018) PICU Length of Stay: Factors Associated With Bed Utilization and Development of a Benchmarking Model. Pediatr Crit Care Med 19:196-203
Bao, Xun; Wu, Jianmei; Sanai, Nader et al. (2018) A liquid chromatography with tandem mass spectrometry method for quantitating total and unbound ceritinib in patient plasma and brain tumor. J Pharm Anal 8:20-26
Heath, Elisabeth I; Lynce, Filipa; Xiu, Joanne et al. (2018) Racial Disparities in the Molecular Landscape of Cancer. Anticancer Res 38:2235-2240

Showing the most recent 10 out of 826 publications